Literature DB >> 17408854

Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).

Elmar Kaiser1, Peter Schönknecht, Philipp A Thomann, Aoife Hunt, Johannes Schröder.   

Abstract

It is generally accepted that cerebrospinal fluid (CSF) biomarkers such as tau protein, phosphorylated tau protein (threonine 181) and beta-amyloid (1-42) can facilitate early and differential diagnosis of Alzheimer's disease (AD). Since the respective concentrations can only be measured in a number of specialized centers, time to CSF specimen work-up has been considered as crucial for the stability of the respective biomarkers. When shipping of CSF samples is needed for biomarker measurement and immediate freezing of samples is not available, an overnight delay of up to 24h frequently occurs. Therefore, we investigated the potential impact of a 24h delayed freezing on CSF biomarker concentrations and compared it to 2h storage (room temperature, 20 degrees C) and an immediate freezing. First, storage at room temperature for 2h had only marginal, non-significant effects on the concentrations of CSF total tau protein and phospho-tau protein (181) compared to immediate freezing. Second, storage at room temperature for 24h did not significantly affect total tau protein or phospho-tau protein but beta-amyloid (1-42) concentrations which increased significantly compared to the samples frozen immediately. These results indicate that CSF samples for the evaluation of total tau and phospho-tau protein may be kept at room temperature for up to 24h whereas CSF samples for beta-amyloid (1-42) need to be frozen immediately.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408854     DOI: 10.1016/j.neulet.2007.02.045

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15

Review 2.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

Review 3.  Biological fluid biomarkers in neurodegenerative parkinsonism.

Authors:  Michael Eller; David R Williams
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

Review 4.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

5.  β-Amyloid (1-42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Elmar Kaiser; Philipp A Thomann; Marco Essig; Johannes Schröder
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-11-16

6.  Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios.

Authors:  Jamie Toombs; Martha S Foiani; Henrietta Wellington; Ross W Paterson; Charles Arber; Amanda Heslegrave; Michael P Lunn; Jonathan M Schott; Selina Wray; Henrik Zetterberg
Journal:  Alzheimers Dement (Amst)       Date:  2018-03-22

7.  Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease.

Authors:  Piotr Lewczuk; Amélie Gaignaux; Olga Kofanova; Natalia Ermann; Fay Betsou; Sebastian Brandner; Barbara Mroczko; Kaj Blennow; Dominik Strapagiel; Silvia Paciotti; Jonathan Vogelgsang; Michael H Roehrl; Sandra Mendoza; Johannes Kornhuber; Charlotte Teunissen
Journal:  Alzheimers Res Ther       Date:  2018-08-28       Impact factor: 6.982

8.  Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers.

Authors:  Maria João Leitão; Inês Baldeiras; Sanna-Kaisa Herukka; Maria Pikkarainen; Ville Leinonen; Anja Hviid Simonsen; Armand Perret-Liaudet; Anthony Fourier; Isabelle Quadrio; Pedro Mota Veiga; Catarina Resende de Oliveira
Journal:  Front Neurol       Date:  2015-07-08       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.